Boardroom Alpha
Start trial
Boardroom Alpha
TVTX · Current Report (Form 8-K) · Filed May 21, 2026

Travere Therapeutics Inc — Current Report (Form 8-K)

Form
8-K
Filed
May 21, 2026
Period
May 19, 2026
Ticker
TVTX
Accession
0001438533-26-000046
Travere Therapeutics Inc on Boardroom AlphaView on SEC EDGAR
Boardroom Alpha · Filing insights

Stockholders approved amending the 2018 Equity Incentive Plan to add 3 million shares and elected ten directors through 2027.

About Travere Therapeutics Inc
Market cap
$4.0B
1Y TSR
+197.5%
3Y TSR
+37.4%
Board grade
C+
Sector
Healthcare
CEO
Eric M Dube
Last annual meeting: May 19, 2026 · View full Travere Therapeutics Inc profile →
tvtx-20260519

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 8-K
___________________________
Current Report
Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 19, 2026
___________________________
TRAVERE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
___________________________

Delaware
 
001-36257
 
27-4842691
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
3611 Valley Centre Drive, Suite 300
San Diego, CA 92130
(Address of Principal Executive Offices, including Zip Code)

(888) 969-7879
(Registrant’s Telephone Number, including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per share
TVTX
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As discussed below in Item 5.07, Travere Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved the Company’s 2018 Equity Incentive Plan, as amended (the “2018 Plan”), to increase the number of shares of common stock authorized for issuance thereunder by 3,000,000 shares. A summary of the material terms of the 2018 Plan is set forth in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 6, 2026. That summary is qualified in its entirety by reference to the text of the 2018 Plan, which is filed as Exhibit 99.1 hereto and incorporated herein by reference.

Item 5.07     Submission of Matters to a Vote of Security Holders.
On May 19, 2026, the Company held the Annual Meeting. As of March 23, 2026, the record date for the Annual Meeting, 92,369,812 shares of common stock were outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 81,108,473 shares of common stock were present in person or represented by proxy for the five proposals summarized below.
Proposal 1: Election of Directors
The Company’s stockholders elected the ten persons listed below to serve until the Company’s 2027 Annual Meeting of Stockholders. The final voting results are as follows:
 Votes For Votes Withheld Broker Non-Votes
Roy D. Baynes, M.D., Ph.D.66,479,9999,338,1495,290,327
Suzanne Bruhn, Ph.D.74,711,9941,106,1545,290,327
Timothy Coughlin73,695,9652,122,1835,290,327
Eric Dube, Ph.D.75,095,860722,2885,290,327
Gary Lyons74,208,9521,609,1965,290,327
Jeffrey Meckler73,469,2632,348,8855,290,327
John A. Orwin74,657,4721,160,6765,290,327
Sandra Poole74,551,1381,267,0105,290,327
Ron Squarer74,767,4551,050,6935,290,327
Ruth Williams-Brinkley74,764,6791,053,4695,290,327
Proposal 2: Approval of the Company’s 2018 Equity Incentive Plan, as amended
The Company’s stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 3,000,000. The final voting results are as follows:
Votes For 72,998,395
Votes Against 2,787,402
Abstentions 32,347
Broker Non-Votes 5,290,327
Proposal 3: Approval, on an advisory basis, of the compensation of the Company’s named executive officers
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The final voting results are as follows:
Votes For 73,711,670
Votes Against 2,073,324
Abstentions 33,152
Broker Non-Votes 5,290,327
Proposal 4: Indication, on an advisory basis, of the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers
The Company’s stockholders indicated, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows:


One Year 75,003,558
Two Years 4,996
Three Years 766,756
Abstentions42,836
Broker Non-Votes 5,290,327
Proposal 5: Ratification of the Selection of Independent Registered Public Accounting Firm
The Company’s stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:
Votes For 80,708,265
Votes Against 120,699
Abstentions 279,509
Broker Non-Votes —
Item 9.01    Financial Statements and Exhibits.
(d)    Exhibits
Exhibit No.Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document).



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
    TRAVERE THERAPEUTICS, INC.
    
Dated: May 21, 2026   By:/s/ Elizabeth E. Reed
      Name:Elizabeth E. Reed
Title:Chief Legal Officer, General Counsel & Secretary


From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

See Filings IntelligenceSchedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Travere Therapeutics Inc (TVTX)

Continue researching
Reference

Frequently asked questions

When did Travere Therapeutics Inc file this 8-K?
Travere Therapeutics Inc (TVTX) filed this Current Report (Form 8-K) with the SEC on May 21, 2026. The accession number assigned by EDGAR is 0001438533-26-000046.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Stockholders approved amending the 2018 Equity Incentive Plan to add 3 million shares and elected ten directors through 2027. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Travere Therapeutics Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Travere Therapeutics Inc has filed under CIK 1438533, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer